Haemophilia Trial, Recruiting NCT06992076 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Haemophilia
Back to Haemophilia

Haemophilia Trial, Recruiting

NCT06992076
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with hemophilia A or hemophilia B and whose treating doctor has determined they are suitable to receive preventive treatment (prophylaxis).
  • People whose treating doctor has prescribed marstacimab for routine preventive treatment, in line with the approved use of the medication.
  • People aged 12 years or older (including both adolescents aged 12 to 17 and adults aged 18 and over).
  • People who have signed a consent form before the study begins — this can be signed by the participant, a legally authorised representative, or a caregiver who is able to provide consent on their behalf.

Who may not be able to join:

  • People who, in the treating doctor's judgement, are unlikely to be able to complete at least one month of follow-up.
  • People with severe difficulties with speech, vision, memory, or thinking that would affect their ability to communicate, complete questionnaires, or attend follow-up visits.
  • Women of childbearing age who are planning to become pregnant within the next 2 months, or who are currently pregnant or breastfeeding.
  • People who are currently taking part in another clinical trial.
  • People who have other conditions that the investigator considers unsuitable for participation in this study (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 022-23608174

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
15 February 2026
Est. completion
31 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

patient preferences for subcutaneous; To assess the treatment burden

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov